🚀 VC round data is live in beta, check it out!
TScan Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for TScan Therapeutics and similar public comparables like Instil Bio, Circio Holding, InflaRx, Mereo BioPharma Group and more.
TScan Therapeutics Overview
About TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Founded
2018
HQ
Employees
195
Website
Sectors
Financials (LTM)
Market Cap
$61M
TScan Therapeutics Financials
TScan Therapeutics reported last 12-month revenue of $10M and negative EBITDA of ($123M).
In the same LTM period, TScan Therapeutics generated $10M in gross profit, ($123M) in EBITDA losses, and had net loss of ($125M).
Revenue (LTM)
TScan Therapeutics P&L
In the most recent fiscal year, TScan Therapeutics reported revenue of $10M and EBITDA of ($121M).
TScan Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | $10M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($123M) | XXX | ($121M) | XXX | XXX | XXX |
| EBITDA Margin | (1241%) | XXX | (1174%) | XXX | XXX | XXX |
| EBIT Margin | (1298%) | XXX | (1293%) | XXX | XXX | XXX |
| Net Profit | ($125M) | XXX | ($130M) | XXX | XXX | XXX |
| Net Margin | (1256%) | XXX | (1257%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TScan Therapeutics Stock Performance
TScan Therapeutics has current market cap of $61M.
Market Cap Evolution
TScan Therapeutics' stock price is $1.08.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $61M | 0.0% | XXX | XXX | XXX | $-2.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTScan Therapeutics Valuation Multiples
TScan Therapeutics trades at (2.8x) EV/Revenue multiple, and 0.2x EV/EBITDA.
EV / Revenue (LTM)
TScan Therapeutics Financial Valuation Multiples
As of March 18, 2026, TScan Therapeutics has market cap of $61M.
Equity research analysts estimate TScan Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TScan Therapeutics has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61M | XXX | $61M | XXX | XXX | XXX |
| EV (current) | ($28M) | XXX | ($28M) | XXX | XXX | XXX |
| EV/Revenue | (2.8x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | (2.8x) | XXX | — | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TScan Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TScan Therapeutics Margins & Growth Rates
TScan Therapeutics' revenue in the last 12 month declined by (16%).
TScan Therapeutics' revenue per employee in the last FY averaged $0.1M.
TScan Therapeutics' rule of 40 is (1256%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TScan Therapeutics' rule of X is (1280%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
TScan Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (16%) | XXX | (18%) | XXX | XXX | XXX |
| EBITDA Margin | (1241%) | XXX | (1174%) | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1256%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1280%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 311% | XXX | 304% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1093% | XXX | 1106% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1415% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TScan Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Instil Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Mereo BioPharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| BeyondSpring | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TScan Therapeutics M&A Activity
TScan Therapeutics acquired XXX companies to date.
Last acquisition by TScan Therapeutics was on XXXXXXXX, XXXXX. TScan Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TScan Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTScan Therapeutics Investment Activity
TScan Therapeutics invested in XXX companies to date.
TScan Therapeutics made its latest investment on XXXXXXXX, XXXXX. TScan Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TScan Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TScan Therapeutics
| When was TScan Therapeutics founded? | TScan Therapeutics was founded in 2018. |
| Where is TScan Therapeutics headquartered? | TScan Therapeutics is headquartered in United States. |
| How many employees does TScan Therapeutics have? | As of today, TScan Therapeutics has over 195 employees. |
| Who is the CEO of TScan Therapeutics? | TScan Therapeutics' CEO is Gavin MacBeath. |
| Is TScan Therapeutics publicly listed? | Yes, TScan Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of TScan Therapeutics? | TScan Therapeutics trades under TCRX ticker. |
| When did TScan Therapeutics go public? | TScan Therapeutics went public in 2021. |
| Who are competitors of TScan Therapeutics? | TScan Therapeutics main competitors are Instil Bio, Circio Holding, InflaRx, Mereo BioPharma Group. |
| What is the current market cap of TScan Therapeutics? | TScan Therapeutics' current market cap is $61M. |
| What is the current revenue of TScan Therapeutics? | TScan Therapeutics' last 12 months revenue is $10M. |
| What is the current revenue growth of TScan Therapeutics? | TScan Therapeutics revenue growth (NTM/LTM) is (16%). |
| What is the current EV/Revenue multiple of TScan Therapeutics? | Current revenue multiple of TScan Therapeutics is (2.8x). |
| Is TScan Therapeutics profitable? | No, TScan Therapeutics is not profitable. |
| What is the current EBITDA of TScan Therapeutics? | TScan Therapeutics has negative EBITDA and is not profitable. |
| What is TScan Therapeutics' EBITDA margin? | TScan Therapeutics' last 12 months EBITDA margin is (1241%). |
| What is the current EV/EBITDA multiple of TScan Therapeutics? | Current EBITDA multiple of TScan Therapeutics is 0.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.